Ribes – Blackcurrant Leaf (Ribis nigri folium)
|Latin name of the genus:||Ribes|
|Latin name of herbal substance:||Ribis nigri folium|
|Botanical name of plant:||Ribes nigrum l.|
|English common name of herbal substance:||Blackcurrant leaf|
Latin name of the genus: Ribes
Latin name of herbal substance: Ribis nigri folium
Botanical name of plant: Ribes nigrum L.
English common name of herbal substance: Blackcurrant Leaf
- 1. Introduction
- 2. Historical data on medicinal use
- 3. Non-Clinical Data
- 3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof
- 3.1.1. Assessor’s overall conclusions on pharmacology
- 3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof
- 3.2.1. Assessor’s overall conclusions on pharmacokinetics
- 3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof
- 3.3.1. Assessor’s overall conclusions on toxicology
- 3.4. Overall conclusions on non-clinical data
- 4. Clinical Data
- 4.1. Clinical Pharmacology
- 4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents
- 4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents
- 4.2. Clinical Efficacy1
- 4.2.1. Dose response studies
- 4.2.2. Clinical studies (case studies and clinical trials)
- 4.2.3. Clinical studies in special populations (e.g. elderly and children)
- 4.3. Overall conclusions on clinical pharmacology and efficacy
- 5. Clinical Safety/Pharmacovigilance
- 5.1. Overview of toxicological/safety data from clinical trials in humans
- 5.2. Patient exposure
- 5.3. Adverse events
- 5.4. Serious adverse events and deaths
- 5.5. Laboratory findings
- 5.6. Safety in special populations and situations
- 5.6.1. Intrinsic (including elderly and children) /extrinsic factors
- 5.6.2. Drug interactions
- 5.6.3. Use in pregnancy and lactation
- 5.6.4. Overdose
- 5.6.5. Drug abuse
- 5.6.6. Withdrawal and rebound
- 5.6.7. Effects on ability to drive or operate machinery or impairment of mental ability
- 5.7. Overall conclusions on clinical safety
- 6. Overall conclusions
Handbooks as well as publications (PubMed & local journals) were used as sources. Keywords: Ribes nigrum, blackcurrant, cassis.
1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof
Blackcurrant leaf consists of the dried leaves of Ribes nigrum L. (blackcurrant), belonging to the family of the Grossulariaceae. The genus Ribes contains between 140 and 150 species. The leaves are collected during or shortly after flowering (Pharm. Française 1996; Hänsel et al. 1994).
A dark green upper surface and a pale greyish green lower surface is characteristic for the slightly wrinkled leaf fragments. Furthermore a widely spaced reticulate venation is particularly distinct on the lower surface. Glands can be seen as scattering yellowish dots. In contrast with the fresh leaves, the dried leaves have no odour or taste. There are no falsifications as the herbal substance is harvested from cultivation (Wichtl 1994; Hänsel et al. 1994).
The dried Ribes nigrum leaf contains not less than 1.5% of flavonoids, expressed as rutin. The material complies with the monograph of the Pharmacopée Française (1996) (ESCOP, 2003).
The most important secondary metabolites present in the herbal substance can be subdivided into several groups of phytochemical compounds.
Polyphenolic substances, more particularly flavonoid glycosides: kaempferol, quercetin.
Hydroxycinnamic acid derivatives: chlorogenic acid and chlorogenic acid derivatives (isochlorogenic acid, neochlorogenic acid), caffeic acid, gallic acid, ferulic acid, coumaric acid, gentisinic acid (Trajkovski, 1974a; Trajkovski 1974b).
Some substances can seasonally appear in the glands of leaves of Ribes nigrum. Sakuranetin is a methylated flavanone aglycone
Figure 1: sakuranetin
Prodelphinidins (proanthocyanidines) were identified in a methanolic extract of the leaves. They may be responsible for the
Figure 2: dimer prodelphinidin I
The presence of glycerolipids has been reported. The total fatty acid composition was unusual, because the following unsaturated fatty acids were identified: linolenic acid
Ascorbic acid is present: between 100 and 270 mg per 100 g dried material (Hänsel et al. 1994).
The essential oil of the leaves of Ribes nigrum contains mainly monoterpenic substances like alpha- pinene, myrcene,
1.2. Information about products on the market in the Member States
Regulatory status overview
MA: Marketing Authorisation TRAD: Traditional Use Registration
Other TRAD: Other national Traditional systems of registration Other: If known, it should be specified or otherwise add ’Not Known’
This regulatory overview is not legally binding and does not necessarily reflect the legal status of the products in the MSs concerned.
1.3. Search and assessment methodology
2. Historical data on medicinal use
2.1. Information on period of medicinal use in the Community
Indications exclusively in folk medicine are: arthritis, rheumatic complaints, diarrhoea, spasmodic cough. Rarely preparations were locally applied on wounds (Wichtl, 1994). Ribes has been traditionally used as an infusion to cure joint complaints (traditionally classified as ‘rheumatism’) (Leclerc 1983; Rombi 1991). The only indication mentioned in the ESCOP monograph is ‘adjuvant in the treatment of rheumatic conditions’ (ESCOP, 2003).
•Dried leaves as an infusion: from 1.5 to 4 g per cup (= 150 ml;
•Fluid extract (1:1): 5 ml 2x daily. The extraction solvent is not specified.
Leaves of Ribes nigrum were mainly used in folk medicine as a diuretic, eliminating uric acid. The preparations mentioned are aqueous decoctions (Decaux, 1930; Hänsel et al. 1994).
Some authors mention the use of tea preparations containing Ribes nigrum, Fraxinus excelsior and
The essential oil of Ribes nigrum should stimulate the renal epithelium and enhance diuresis (Garnier et al. 1961; Rombi 1991).
Leaves were applied on the head against migraine (Decaux, 1930).
Justification for acceptance of herbal preparations in the monograph
•Powdered herbal substance in capsules has been marketed in France (since 1988) and in Spain (since 1991) in different posologies (France: 340 mg up to 5 capsules per day; Spain: 250 mg up to 6 capsules per day). The period of use covers 15 years in Europe but is not fulfilling the 30 years of traditional use as stipulated in Directive 2001/83/EC [article 16b paragraph (c)]. The company provided evidence for a market introduction of a capsule containing 260 mg of ‘cassis’ powder in 1983. This would mean that the preparation could be included in the monograph from 2013 on.
•Dry extract (7:1; extraction solvent water) is marketed in France as capsules (169 mg per capsule; posology: up to 3 capsules daily) meets the 15 year tradition in Europe and does not comply with the 30 years of traditional use as stipulated in Directive 2001/83/EC [article 16b paragraph (c)]. Nevertheless during its meeting of 12 January 2010 the MLWP decided to accept this preparation based upon the following justification:
•– The extract is made with water, a procedure close to herbal tea preparations.
infused; virtually, more material can be extracted by preparing the herbal tea. The number of daily doses is similar for the extract and the infusion.
•Topical use is not granted, because there are no preparations and posology specified (cf. Poland).
2.2.Information on traditional/current indications and specified substances/preparations
2.3.Specified strength/posology/route of administration/duration of use for relevant preparations and indications
3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof
– Biosynthesis and release of prostaglandins
The experimental model was the isolated heart of the rabbit with arachidonic acid as substrate (100 µg). The preparation consisted of purified flavonoid substances, but no further data about the exact composition are available.
The prostaglandins released in the heart effluent were detected by means of bioassay, using the rat stomach strip.
Total flavonoids extracted from the leaves of Ribes nigrum, inhibited both biosynthesis and release of
Chondrocytes and COX
The experimental model consisted of cultured human chondrocytes from cartilage isolated after surgery and
The herbal preparation consisted of leaf extract made with acetone (70% v/v in water). The resulting condensed tannins were purified using reversed phase and Sephadex LH20 column chromatography. The proanthocyanidines were purified to 95%. Purification yielded among others catechin, gallocatechin,
Several effects of these purified fractions were evaluated on the cultivated chondrocytes:
•A positive effect on the production of proteoglycans with concentrations from 1 to 100 µg/ml.
•A positive effect on type II collagen production with concentration from 1 to 100 µg/ml.
•An inhibitory effect on the prostaglandin E2 (PGE2) production mainly with concentrations from 10 to 100 µg/ml.
Isolated prodelphinidines had an inhibitory effect on the biosynthesis of prostaglandins catalyzed by
The experimental model consisted of an LT2 cell line originating from human umbilical vein endothelium cells.
A significant inhibition of
– Antilipoperoxidative effects
Methanolic crude extracts of fruits, leaves and buds of Ribes nigrum were tested in rat hepatic microsomes. The extracts contained between 818 to 997 mg polyphenols per 100g leaves. The oxidative mixture consisted of a Fe++ (FeSO4) and ADP mixture in the presence of ascorbic acid.
Antilipoperoxidative effects were measured by quantifiying the amount of malondialdehyde. The IC50 of the extracts varied between 9.31 and 6.44 µg/ml (Costantino et al. 1993).
ED50 = effective dose in 50% of animals
Indo = indomethacin
IP = intraperitoneal
LD50 = lethal dose in 50% of animals
Nifl = niflumic acid
PACs = proanthocyanidines
PMNs = polymorphonuclear leukocytes
PO = peroral
Rn = Ribes nigrum
RP = reversed phase (chromatography)
– Diuretic activity
The model used was a salidiuretic action. The intervention consisted of oral administration of a fluid extract (1:1) of blackcurrant leaf. The diuretic action of an equivalent of 1500 mg dried leaf/kg was comparable to the effect of furosemide at 50 mg/kg
– Antihypertensive effects
The model used was the antihypertensive effect on cats. Doses liquid extract (1:1) equivalent to of 400 mg dried blackcurrant leaf/kg were compared to tolazoline 0.75 mg/kg and 1.0 mg/kg. The antihypertensive effects of both were comparable, but the effect of the leaf extract lasted for 20 minutes as compared to 5 minutes for tolazoline
In another study normotensive rats were used. An infusion of blackcurrant leaf (20g/L) was administered intravenously at a dose equivalent to 360 mg dried leaf per kg. There was a 45% fall in blood pressure, which after 30 minutes was still 30% (Laserre et al. 1983).
3.1.1. Assessor’s overall conclusions on pharmacology
Most of the experimental in vivo pharmacology with Ribes nigrum herbal preparations was done on models of inflammation: carrageenin paw oedema, cotton pellet granuloma test and carrageenin induced pleurisy. Rats were the species used. The preparations consisted mainly of alcoholic liquid extracts which were mostly lyophilized. They were administered perorally as well as intraperitoneally. Ribes nigrum performed qualitatively and quantitatively well as compared to non steroidal anti- inflammatory substances like indomethacin, nifluminic acid and acetylsalicylic acid. Several inflammatory parameters were significantly reversed, especially the formation of oedema and the cellular components as illustrated by reduced exsudate, infiltration of polymorphonuclear leukocytes, release of interleukins and cytokines and the formation
Apart from the
In vitro experiments confirmed the
Additional properties emerged from in vitro experiments with human chondrocytes. Purified proanthocyanidins stimulated the biosythesis of proteoglycans and collagen. This can be considered as an activity complementary to the treatment of inflammation. Furthermore proanthocyanidins inhibited the formation of tumor necrosis factor α and the intracellular adhesion molecule in human endothelial cells. Finally antilipoperoxydase effect can be added to this large scope of activities.
As a conclusion, an overview of the experimental pharmacology of Ribes nigrum preparations opens perspective for further clinical investigations in human subjects.
3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof
No data with regard to absorption, distribution, metabolism, elimination and pharmacokinetic interactions with other medicinal products are available.
3.2.1. Assessor’s overall conclusions on pharmacokinetics
3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof
– Acute toxicity
Mice were used as animal species. Ribes nigrum leaf was administered intraperitoneally as liquid extract (1:1). The intraperitoneal LD0 and LD50 were 22 and 49 g/kg respectively. The LD100 was estimated at 90 g/kg (ESCOP, 2003).
In another study with mice a lyophilizate obtained by maceration of 100 g leaf per litre 15% ethanol was administered. Intraperitoneal LD50 was 1.09 g/kg. Oral doses up to 3 g/kg did not show overt toxicity (ESCOP, 2003; Mongold 1993).
– Subacute toxicity
Rats were used as animal species. Ribes nigrum leaf was administered as a lyophilized 15% ethanolic extract (1 g of extract was equivalent to 1.8 g of leaf). The extract was administered orally in daily doses of 2 g/kg/day (21 days) and 1.34 g/kg/day (28 days) respectively. No signs of toxicity or gastric ulceration were observed (ESCOP, 2003).
Rats were used as animal species. Ribes nigrum leaf was administered as a lyophilizate obtained by maceration of 100 g leaf per liter 15% ethanol. The extract was administered orally during 10 days without specification of the dose. No change in feeding pattern, fluid consumption or body weight was seen. Blood analysis and histopathological evaluation of 14 organs did not reveal any abnormalities (ESCOP, 2003, Mongold 1993).
– Chronic toxicity
Feeding mice with a daily dose of 3 g/kg of dried leaves during 6 months did not reveal any toxicity (Hänsel et al. 1994).
3.3.1. Assessor’s overall conclusions on toxicology
No signs of major toxicity can be seen. In contrast of what could be expected from preparations able to inhibit
3.4. Overall conclusions on
4. Clinical Data
4.1. Clinical Pharmacology
4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents
No clinical data available.
22.214.171.124. Assessor’s overall conclusions on pharmacodynamics
4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents
No data available.
126.96.36.199. Assessor’s overall conclusions on pharmacokinetics
4.2. Clinical Efficacy1
4.2.1. Dose response studies
No dose response studies available.
4.2.2. Clinical studies (case studies and clinical trials)
No clinical studies reported.
4.2.3. Clinical studies in special populations (e.g. elderly and children)
No clinical studies in special populations reported.
4.3. Overall conclusions on clinical pharmacology and efficacy
1 In case of traditional use the
5. Clinical Safety/Pharmacovigilance
5.1. Overview of toxicological/safety data from clinical trials in humans
No data collected.
5.2. Patient exposure
No data available.
5.3. Adverse events
No data available.
5.4. Serious adverse events and deaths
5.5. Laboratory findings
5.6. Safety in special populations and situations
Oedema due to heart failure or renal insufficiency is mentioned as a possible
5.6.1. Intrinsic (including elderly and children) /extrinsic factors
No data available.
5.6.2. Drug interactions
No data available.
5.6.3. Use in pregnancy and lactation
No data available.
No data available.
5.6.5. Drug abuse
No data available.
5.6.6. Withdrawal and rebound
No data available.
5.6.7. Effects on ability to drive or operate machinery or impairment of mental ability
No data available.
5.7. Overall conclusions on clinical safety
6. Overall conclusions
There is a lot of interesting experimental work done in vitro as well in vivo with preparations of Ribes nigrum. The results of these studies substantiate the traditional use of blackcurrant leaves in inflammatory conditions. There is experimental evidence for an additional analgesic activity. No signs of general or
As a consequence the clinical perspective of Ribes nigrum leaves and its preparations may be promising. Up to now clinical data are totally absent which means that the herbal drug and herbal preparations thereof can only be considered as traditionally used.
According to the ORGAM proposal2 a
The herbal medicinal substance is not yet described in the European Pharmacopoeia, but there are other standard references as the quality of the raw material is concerned (French Pharmacopoeia, Hagers Handbuch and ESCOP). By these descriptions a clear definition of the raw material can be guaranteed. The herbal substance can be identified without too much difficulty. Moreover, there is a characteristic smell due to the essential oil content.
There are no published reports on serious side effects when taking therapeutic doses or after (in)voluntary intoxications with the herbal substance or herbal preparations thereof. Secondary metabolites of Ribes nigri folium have a polyphenolic character and can be considered as antioxidants. Acute or chronic preclinical toxicity investigations are no subject to any major concerns. Nevertheless, polyphenols can be harmful in high concentrations and high daily intake in concentrated form. There is still a need for the investigation of genotoxic, mutagenic and cancerogenic properties in order to facilitate a list entry.
The pathological conditions for which Ribes nigri folium is used are mostly symptomatically approached. There are no conditions when they should be avoided. In inflammatory conditions a symptomatic approach is made. When comparing the herbal substance with the medicines actually in use, the effectiveness of the former is only preclinically documented. Nevertheless, the use of Ribes nigri folium and preparations thereof seems safer concerning side effects, more particularly gastrointestinal side effects. Actually the possible therapeutic consequences of a hypothesized diuretic action of Ribes nigri folium cannot be compared with the clinical significance of the actual diuretics used in cardiovascular prevention and treatment. It is not recommendable to use the herbal substance or preparations thereof in this therapeutic context.
There are no concerns of possible drug interactions. The use is not recommended in children and during pregnancy and lactation. This precaution is because safety data is lacking: there are no real indications for use in these groups at risk.
The herbal substance has been on the market for more than 30 years in some European countries. As the plant belongs to the European fauna of the mixed climate zone and the berries have been well known3, traditional use of the leaves is much older and dates probably back for centuries.
List of references
3 The use of leaves has already been mentioned by Rembertus Dodonaeus in his ‘Herbarius ofte